Rallybio Corp (RLYB) News

Rallybio Corp (RLYB): $14.47

0.01 (+0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RLYB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter RLYB News Items

RLYB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RLYB News Highlights

  • For RLYB, its 30 day story count is now at 4.
  • Over the past 28 days, the trend for RLYB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about RLYB are CONN, MA and RARE.

Latest RLYB News From Around the Web

Below are the latest news stories about RALLYBIO CORP that investors may wish to consider to help them evaluate RLYB as an investment opportunity.

JMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYB - Research Report) today and set a price target of $36.00. The company's shares opened today at $13.53.Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -7.9% and a 36.03% success rate on recommended stocks. Rallybio has an analyst consensus of Moderate Buy, with a price target consensus of $36.00.See today’s best-performing stocks on TipRanks >>Based on Rallybio's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.58 million.

Catie Powers on TipRanks | September 28, 2022

Rallybio's Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets

Rallybio Corporation (NASDAQ: RLYB) announced preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212 to prevent fetal and neonatal alloimmune thrombocytopenia. The data demonstrate that one week after a single subcutaneous dose, RLYB212 could rapidly eliminate transfused HPA-1a positive platelets compared to placebo in a challenge model of a catastrophic fetal-maternal hemorrhage. Additional pharmacokinetic data suggests the opportunity for less frequent dosing. Consiste

Yahoo | September 28, 2022

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

NEW HAVEN, Conn., September 28, 2022--Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Yahoo | September 28, 2022

Rallybio to Present at the 2022 Wells Fargo Healthcare Conference

NEW HAVEN, Conn., August 31, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:10 p.m. ET in Everett, MA.

Yahoo | August 31, 2022

JMP Securities Keeps Their Buy Rating on Rallybio (RLYB)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB - Research Report), with a price target of $34.00. The company's shares opened today at $11.29.Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Madrigal Pharmaceuticals. According to TipRanks, Wolleben has an average return of -3.2% and a 45.76% success rate on recommended stocks. Currently, the analyst consensus on Rallybio is a Moderate Buy with an average price target of $34.00.See the top stocks recommended by analysts >>The company has a one-year high of $21.00 and a one-year low of $5.90.

Christine Brown on TipRanks | August 8, 2022

Rallybio Reports Second Quarter 2022 Financial Results

NEW HAVEN, Conn., August 08, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments.

Yahoo | August 8, 2022

Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

NEW HAVEN, Conn., August 02, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors.

Yahoo | August 2, 2022

Multiple insiders bought Rallybio Corporation (NASDAQ:RLYB) stock earlier this year, a positive sign for shareholders

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Yahoo | July 6, 2022

Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer

NEW HAVEN, Conn., June 02, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO). Mr. Fryer will continue to serve as Rallybio’s CFO until a new CFO has been appointed and will retire from the Company following a transition period. Ral

Yahoo | June 2, 2022

Rallybio to Present at Upcoming Investor Conferences in June

NEW HAVEN, Conn., June 01, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

Yahoo | June 1, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5163 seconds.